<DOC>
	<DOCNO>NCT00193037</DOCNO>
	<brief_summary>The efficacy single agent liposomal doxorubicin compare single agent docetaxel evaluate first line treatment metastatic breast cancer patient , subsequent crossover opposite arm disease progression patient intolerance . We explore well possible cross resistance two agent .</brief_summary>
	<brief_title>Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel Patients First Relapse Metastatic Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient randomly assign one two treatment arm : - Liposomal Doxorubicin - Docetaxel For ever 2 patient treat , 1 receive treatment A ( Liposomal Doxorubicin ) 1 receive treatment B ( Docetaxel ) . Patients demonstrate progression either ARM eligible cross treatment ARM , provide patient still meet eligibility laboratory performance status criterion . The study blind patient doctor know treatment assign .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic breast cancer confirm biopsy Prior adjuvant/neoadjuvant treatment allow Measurable disease Able perform activity daily live minimal assistance Age 18 year old Adequate bone marrow , liver kidney function Normal heart function Written inform consent You participate study follow apply : Preexisting moderate peripheral neuropathy History significant heart disease Meningeal metastases . Prior chemotherapy metastatic breast cancer No measurable disease ( include bone , pleural effusion , etc . ) Receiving Herceptin therapy . Women pregnant lactating . Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>